Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.
MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS
申请人:Pfizer Inc.
公开号:EP2569310A1
公开(公告)日:2013-03-20
[EN] MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS MORPHOLINIQUES CONVENANT COMME ANTAGONISTES DE RÉCEPTEURS DE MINÉRALCORTICOÏDES
申请人:PFIZER
公开号:WO2011141848A1
公开(公告)日:2011-11-17
Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.
Epoxyamines. III. Synthesis and reactions of 2-(1-aziridinyl)-2-phenyl-3,3-dimethyloxirane and 2-(1-aziridinyl)-2-phenyl-1-oxaspiro[2.4]heptane
作者:Calvin L. Stevens、John M. Cahoon、Thomas R. Potts、P. Madhavan Pillai